Proteasome inhibition paradoxically degrades gain-of-function mutant p53 R273H in NSCLC and could have therapeutic implications

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Lung cancer remains a leading cause of cancer mortality globally.
• Mutant p53, prevalent in lung cancers, drives oncogenesis and predicts poor prognosis.
• Targeting mutant p53 stability is a potential therapeutic strategy, but clinical success has been limited.

Purpose of the Study:

• To investigate the effect of proteasome inhibition on mutant p53 degradation in non-small cell lung cancer (NSCLC).
• To explore the role of hsp70 in mediating mutant p53 degradation.
• To assess the therapeutic potential of proteasome inhibitors in NSCLC with specific TP53 mutations.

Main Methods:

• Utilized NSCLC cell lines harboring the R273H mutant p53 protein.
• Administered proteasome inhibitors to study their effect on mutant p53 levels.
• Investigated the involvement of hsp70 in the degradation pathway.
• Assessed cell susceptibility and apoptosis induction by proteasome inhibitors.

Main Results:

• Proteasome inhibition led to the degradation of mutant p53 in R273H-mutated NSCLC cell lines.
• Evidence suggests hsp70 mediates this degradation process.
• NSCLC cell lines with the R273H mutation showed increased sensitivity and apoptosis upon treatment with proteasome inhibitors.

Conclusions:

• Proteasome inhibition effectively degrades mutant p53 in specific NSCLC contexts.
• Hsp70 plays a role in the proteasome inhibitor-induced degradation of mutant p53.
• Proteasome inhibitors represent a promising therapeutic avenue for subsets of NSCLC patients with TP53 mutations.